Arteaga C L, Hurd S D, Dugger T C, Winnier A R, Robertson J B
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.
Cancer Res. 1994 Sep 1;54(17):4703-9.
Epidermal growth factor (EGF) receptors are expressed in high levels by some poor prognosis breast tumors. We have examined the cytotoxic effect of the tumor growth factor alpha (TGF alpha)-delta Cys-Pseudomonas exotoxin (PE40) recombinant fusion protein on normal and tumorigenic human breast epithelial cells in vitro and in vivo. The MDA-468, MDA-231, BT-20, and MCF-7ADR estrogen receptor-negative, EGF receptor-rich breast cancer lines were exquisitely sensitive in vitro to TGF alpha-delta Cys-PE40 with a 50% inhibitory concentration of < or = 0.02 nM. The estrogen receptor-positive, low EGF receptor MCF-7, ZR75-1, and T47D cells were less sensitive to the fusion toxin with a 50% inhibitory concentration of > 0.2 nM. The nontumorigenic cell lines 184, 184A1, and 184B5 were relatively resistant to TGF alpha-delta Cys-PE40 despite exhibiting high levels of EGF receptors. Continuous i.p. administration of TGF alpha-delta Cys-PE40 via an osmotic minipump at a dose of 0.4 microgram/g/day over 7 days inhibited MDA-468, MA-231, and BT-20 but not MCF-7 tumor growth in female athymic mice. Host tissue toxicity was not observed with this dose of TGF alpha-delta Cys-PE40. Mixed MDA-468/MCF-7 tumors were established in nude mice after coinoculation of both cell types in estrogen-supplemented animals. EGF receptor immunohistochemistry and immunoblot procedures indicated that TGF alpha-PE40 eliminated the MDA-468 cells while sparing the adjacent MCF-7 cells. By immunoblot, EGF receptors were consistently more abundant in tumor tissue than in adjacent nontumor tissue from the same mastectomy specimen (n = 7). These data support the notion that EGF receptors can be selectively targeted in human breast cancer cells for the delivery of antitumor agents. Further clinical studies with TGF alpha-delta Cys-PE40 and other chimeric toxins using the same cellular target will address this possibility.
表皮生长因子(EGF)受体在一些预后较差的乳腺肿瘤中高表达。我们已经检测了肿瘤生长因子α(TGFα)-δ半胱氨酸-铜绿假单胞菌外毒素(PE40)重组融合蛋白在体外和体内对正常及致瘤性人乳腺上皮细胞的细胞毒性作用。MDA-468、MDA-231、BT-20和MCF-7ADR雌激素受体阴性、富含EGF受体的乳腺癌细胞系在体外对TGFα-δ半胱氨酸-PE40极为敏感,50%抑制浓度≤0.02 nM。雌激素受体阳性、EGF受体低表达的MCF-7、ZR75-1和T47D细胞对融合毒素的敏感性较低,50%抑制浓度>0.2 nM。非致瘤性细胞系184、184A1和184B5尽管表达高水平的EGF受体,但对TGFα-δ半胱氨酸-PE40相对耐药。通过渗透微型泵以0.4微克/克/天的剂量连续腹腔注射TGFα-δ半胱氨酸-PE40 7天,可抑制雌性无胸腺小鼠体内MDA-468、MA-231和BT-20肿瘤生长,但对MCF-7肿瘤生长无抑制作用。该剂量的TGFα-δ半胱氨酸-PE40未观察到宿主组织毒性。在雌激素补充的动物中同时接种两种细胞类型后,在裸鼠体内建立了混合的MDA-468/MCF-7肿瘤。EGF受体免疫组织化学和免疫印迹程序表明,TGFα-PE40消除了MDA-468细胞,而使相邻的MCF-7细胞得以保留。通过免疫印迹法检测,在同一切除标本(n = 7)中,肿瘤组织中的EGF受体始终比相邻的非肿瘤组织中更为丰富。这些数据支持了EGF受体可在人乳腺癌细胞中被选择性靶向用于递送抗肿瘤药物的观点。使用相同细胞靶点对TGFα-δ半胱氨酸-PE40和其他嵌合毒素进行进一步的临床研究将探讨这种可能性。